ArticlePediatric blood & cancer2016
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Article in Pediatric blood & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.Scientific reports · 2018Pooled it
- Real-world romiplostim dosing, response and home administration in paediatric immune thrombocytopenia.British journal of haematology · 2026Article
- Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia.Current issues in molecular biology · 2025Review
- Predictors for spontaneous remission in childhood chronic immune thrombocytopenia.Annals of hematology · 2024Article
- Experience with Pediatric Chronic Immune Thrombocytopenia over 30 Years in the Era before Eltrombopag.Children (Basel, Switzerland) · 2024Article
- Real-world experience of thrombopoietin receptor agonists in pediatric immune thrombocytopenia: a report from a Chinese tertiary children's hospital.Translational pediatrics · 2024Article
- Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).Journal of clinical medicine · 2023Review
- Predictor Factors for Chronicity in Immune Thrombocytopenic Purpura in Children.Children (Basel, Switzerland) · 2023Article
- Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.Blood advances · 2021Observational
- Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.Annals of hematology · 2021Review
- Article
- Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.Research and practice in thrombosis and haemostasis · 2021Article
- Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients.Frontiers in pharmacology · 2021Article
- Immune Thrombocytopenia in Children: Consensus and Controversies.Indian journal of pediatrics · 2020Review
- Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP).Frontiers in medicine · 2020Article
- The role of romiplostim for pediatric patients with immune thrombocytopenia.Therapeutic advances in hematology · 2020Review
- Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use.Patient preference and adherence · 2020Review
- [Eltrombopag for the treatment of primary immune thrombocytopenia in 23 pediatric patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia.Blood advances · 2019Article
- The child with immune thrombocytopenia: to treat or not to treat, is that still the question?Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundData on second-line treatment options for pediatric patients with immune thrombocytopenia (ITP) are limited. Thrombopoietin receptor agonists (TPO-RA) provide a nonimmunosuppressive option for children who require an increased platelet count. PROCEDURE: We performed a multicenter retrospective study of pediatric ITP patients followed at ITP Consortium of North America (ICON) sites to characterize TPO-RA use.
resultsSeventy-nine children had a total of 87 treatments (28 eltrombopag, 43 romiplostim, and eight trialed on both). The majority had primary ITP (82%) and most (60.8%) had chronic ITP. However, 22% had persistent ITP and 18% had newly diagnosed ITP. During the first 3 months of treatment, 89% achieved a platelet count ≥ 50 × 10(9) /l (86% romiplostim, 81% eltrombopag, P = 0.26) at least once in the absence of rescue therapy. The average time to a response was 6.4 weeks for romiplostim and 7.0 weeks for eltrombopag (P = 0.83). Only 40% of patients demonstrated a stable response with consistent dosing over time. An intermittent response with constant dose titration was seen in 15%, and an initial response that waned to no response was seen in 13%. Significant adverse events were minimal with the exception of two patients with thrombotic events and one who developed a neutralizing antibody.
conclusionsOur results demonstrate that TPO-RA agents are being used in children with ITP of varying duration and severity. The response was similar to clinical trials, but the sustainability of response varied. Future studies need to focus on the ideal timing and rationale for these medications in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.